Peter J Hoskin

A randomized trial of hypofractionated schedules of palliative radiotherapy in the management of bladder carcinoma: results of medical research council trial BA09.

S. Fosså, M. Parmar, P. Hoskin, 2000, International journal of radiation oncology, biology, physics.

ARCHERY: a prospective observational study of artificial intelligence-based radiotherapy treatment planning for cervical, head and neck and prostate cancer – study protocol

S. Laskar, B. Vanderstraeten, Yolande Lievens, 2023, BMJ Open.

Critical Reviews in Oncology/Hematology

G. Gatta, M. Ceppi, R. Caparica, 2016 .

Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial

A. Espinasse, P. Flohr, B. Gurel, 2024, European journal of cancer.

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)

M. Parmar, M. Sydes, D. Dearnaley, 2022, International journal of cancer.

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.

M. Parmar, M. Sydes, D. Dearnaley, 2023, The Lancet. Oncology.

Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a rapid review

I. F. Tannock, Peter J Hoskin, Ananya Choudhury, 2024, BMJ Oncology.